Production (Stage)
Veracyte, Inc.
VCYT
$27.16
-$0.24-0.88%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.20% | 20.81% | 28.58% | 26.69% | 17.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.20% | 20.81% | 28.58% | 26.69% | 17.50% |
| Cost of Revenue | 2.92% | 26.18% | 22.90% | 13.20% | -19.33% |
| Gross Profit | 25.56% | 18.51% | 31.09% | 33.29% | 50.57% |
| SG&A Expenses | 6.26% | 3.83% | 18.87% | 8.58% | 4.86% |
| Depreciation & Amortization | -12.21% | -20.91% | -28.86% | -29.04% | -31.45% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.30% | 9.09% | 19.22% | 10.83% | 9.86% |
| Operating Income | 290.67% | 334.38% | 286.02% | 167.15% | 55.90% |
| Income Before Tax | 489.31% | 111.30% | 156.59% | 188.93% | 76.42% |
| Income Tax Expenses | 965.91% | 23.36% | 1,199.35% | 1,201.60% | -- |
| Earnings from Continuing Operations | 478.06% | 118.07% | 151.17% | 168.25% | 76.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 478.06% | 118.07% | 151.17% | 168.25% | 76.96% |
| EBIT | 290.67% | 334.38% | 286.02% | 167.15% | 55.90% |
| EBITDA | 880.41% | 372.60% | 72.45% | 1,034.90% | 147.12% |
| EPS Basic | 462.65% | 117.03% | 148.38% | 164.62% | 77.79% |
| Normalized Basic EPS | 918.70% | 298.61% | 214.09% | 193.28% | 80.19% |
| EPS Diluted | 461.45% | 115.84% | 146.34% | 158.33% | 77.79% |
| Normalized Diluted EPS | 898.37% | 286.81% | 208.41% | 192.58% | 80.19% |
| Average Basic Shares Outstanding | 4.37% | 6.16% | 5.78% | 5.60% | 3.58% |
| Average Diluted Shares Outstanding | 7.08% | 9.30% | 7.77% | 6.46% | 3.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |